SCHEMBL3045010

SCHEMBL3045010

CCOC(=O)COc1ccc(I)cc1C(=O)OC

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
ABCB1 P08183 1/20 0.44
CASP3 P42574 1/20 0.44
CASP7 P55210 1/20 0.44
CASP9 P55211 1/20 0.44
HTT P42858 1/20 0.43
ESR1 P03372 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPK1 P28482 1/20 0.41
USP2 O75604 1/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 1/20 0.41
HPGD P15428 1/20 0.41
CASP1 P29466 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
GAA P10253 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2226597 0.89 TDP1 (0.48) ALDH1A1ABCB1CASP3CASP7CASP9
SCHEMBL14108206 0.86 ALDH1A1 (0.53) ALDH1A1ABCB1CASP3CASP7CASP9
SCHEMBL15912482 0.84 PTGDR2 (0.53) ALDH1A1ABCB1CASP3CASP7CASP9
SCHEMBL13616954 0.84 ALDH1A1 (0.51) ALDH1A1ABCB1CASP3CASP7CASP9
SCHEMBL759639 0.84 GAA (0.53) ALDH1A1SMN1; SMN2MAPK1KDM4EMEN1
SCHEMBL22164333 0.83 PTGDR2 (0.49) ALDH1A1HTTSMN1; SMN2MEN1KMT2A
SCHEMBL3962439 0.81 ESR1 (0.56) ALDH1A1CASP3CASP7CASP9ESR1
SCHEMBL25015012 0.81 MAPT (0.48) ALDH1A1HTTSMN1; SMN2KDM4EMEN1
SCHEMBL8716128 0.81 ALDH1A1 (0.48) ALDH1A1ABCB1CASP3CASP7CASP9
SCHEMBL4667829 0.80 MAPT (0.45) ALDH1A1HTTSMN1; SMN2KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100003191-A1 AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS NAGASAKI UNIVERSITY (JP) 2010-01-07 US disclosed
US-20100003191-A1 AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS NAGASAKI UNIVERSITY (JP) 2010-01-07 US disclosed
EP-2113258-A1 AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS Nagasaki University (JP) 2009-11-04 EP disclosed
EP-2113258-A1 AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS Nagasaki University (JP) 2009-11-04 EP disclosed
US-7405299-B2 Compounds as pharmaceutical agents ELI LILLY AND COMPANY (US) 2008-07-29 US disclosed
US-20060058295-A1 Novel compounds as pharmaceutical agents ELI LILLY AND COMPANY (US) 2006-03-16 US disclosed
EP-1370557-B1 BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS PFIZER PROD INC (US) 2005-11-16 EP disclosed
EP-1567527-A1 CONDENSED PYRAZOLO DERIVATIVES ELI LILLY AND COMPANY (US) 2005-08-31 EP disclosed
WO-2004050659-A1 NOVEL COMPOUNDS AS PHARMACEUTICAL AGENTS ELI LILLY AND COMPANY (US) 2004-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058295-A1 Novel compounds as pharmaceutical agents TGFB1, TGFB2, TGFBR1 ALDH1A1 1346/4885ABCB1 46/4885CASP3 2566/4885
US-20100003191-A1 AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS APP, APBA1, BACE1 ALDH1A1 2730/4885ABCB1 367/4885CASP3 2583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.